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Abstract 
Binge eating disorder is characterized by excessive, uncontrollable consumption of 
palatable food within brief periods of time. Excessive intake of palatable food is thought to be 
driven by hedonic, rather than energy homeostatic mechanisms. However, reward processing 
does not only comprise consummatory actions; a key component is represented by the 
anticipatory phase directed at procuring the reward. This phase is highly influenced by 
environmental food-associated stimuli which can robustly enhance the desire to eat even in 
the absence of physiological needs. The opioid system (endogenous peptides and their 
receptors) has been strongly linked to the rewarding aspects of palatable food intake, and 
perhaps represents the key system involved in hedonic overeating. Here we review evidence 
suggesting that the opioid system can also be regarded as one of the systems regulating the 
anticipatory incentive processes preceding binge eating hedonic episodes.  
Introduction 
Binge eating disorder (BED) is characterized by recurrent-persistent episodes of excessive 
and uncontrollable food consumption within a short period of time. Although individuals 
with BED generally have a higher than average body mass index (BMI), weight and BMI are 
not diagnostic criteria for BED. The aberrant eating behaviour behind this disorder is 
characterized by a subjective sense of loss of control, distress, uncomfortable fullness and 
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intense feelings of disgust and embarrassment
1
, without the inappropriate compensatory 
behaviours of bulimia nervosa
2
. Episodes of binge eating, associated with at least three 
specific features (e.g. eating more rapidly than normal, eating until uncomfortably full, eating 
a large amount when not hungry, eating alone because of embarrassment, feeling disgusted, 
depressed, or guilty about overeating) occur both in BED and in bulimia nervosa with an 
average frequency of at least once a week, over three months
2
.  
The lifetime prevalence of frequent binge eating in the United States is about 1.5% with a 
median age of onset of about 12.5 years
3,4
. About 35% of those who regularly binge are 
overweight or obese
5
. Additionally, individuals reporting to engage in binge eating 
behaviours have been shown to regain weight at a faster rate than those who do not
6
. 
Interestingly, among those who binge approximately 76% of adults and 85% of adolescents 
experience psychiatric co-morbidities such as anxiety, mood, and substance use disorders
3
, as 
well as other disorders such as obesity, diabetes, and cardiovascular diseases
7
. Based on the 
growing evidence of high prevalence and clinical significance
8,9
, the fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V) has now designated BED as 
a psychiatric illness distinct from other eating disorders with  a specific formal diagnosis
2
 and 
the only pharmacological treatment for BED, lisdexamfetamine dimesylate, has just recently 
been approved by the Food and Drug Administration (FDA)
10
.  On the other hand, 
medications that have been reported to reduce binge eating in clinical studies, e.g. 
topiramate
11,12
, are associated with a variety of adverse side effects, which may result in 
discontinuation of therapy
13
. 
Unlike individuals with bulimia nervosa, individuals with BED typically do not show 
marked or sustained dietary restriction designed to influence body weight and shape between 
binge-eating episodes. They may, however, report frequent attempts at dieting.. Therefore, a 
widely accepted hypothesis about the etiology of binge eating is based on the sequential 
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access to foods with different hedonic value, as occurs in restrained eaters
14,15
. Highly 
palatable foods are typically rich in sucrose and fat and they are commonly perceived as 
‘forbidden’ between binges because they are calorie-dense16,17. Therefore, selection of low 
energy-dense foods in chronic dieters
18–20
 may instead increase craving for more appetitive 
palatable foods, and makes individuals more vulnerable to behavioural excess and 
overeating
21
. Highly palatable foods are more likely to be consumed for reasons beyond 
hunger, and their high palatability make it more difficult to limit and to control their 
intake
22,23
. 
The opioid system (endogenous peptides and their receptors) has been strongly linked to 
rewarding impact of palatable food intake, and it represents one of the key systems regulating 
hedonic overeating
24
. Opioid receptor agonist administration increases food intake while 
opioid receptor antagonists decrease it
25
. Among the different opioid receptor subtypes, μ-
opioid receptors have been strongly involved in the modulation of hedonic feeding in general 
and more specifically in pathological overeating observed in BED
24
. Motivated behaviours 
are not only characterized by hedonic mechanisms leading to consummatory episodes. 
Anticipatory incentive processes by which an individual comes to expect contact with 
palatable food, e.g. the exposure to cues associated with that specific food, also play a 
fundamental role. A cue may be successfully resisted many times, but on some occasions it 
may trigger irresistible temptation
26,27
. Clinical data have suggested that some individuals 
may attribute a higher motivational value to food-cues compared to others and, therefore, 
these may be more likely to overeat 
28,29
. Indeed, food craving has been reported to be a 
major precipitant of binge episodes
30,31
.  
While emphasizing the results obtained in animal models of binge eating, the present 
review will focus on the role of the opioid system both in the hedonic component of 
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consummatory behaviour and more specifically in anticipatory incentive processes preceding 
binge-eating hedonic episodes. 
Hedonically-driven eating behaviour 
Because consumption of large volumes of palatable food in brief periods of time is the key 
diagnostic criterion for BED, animal models of this disorder have been developed to mimic 
this essential maladaptive behavioural outcome. Table 1 summarizes the most predictive 
binge eating preclinical models, divided into three major classes, as a function of the 
procedures used to induce binge eating in animals: i) binge eating induced by cycles of food 
deprivation and renewed access to a sucrose solution; ii) binge eating induced by cycles of 
stress and food restriction/refeeding; iii) binge eating induced by limiting access to a highly 
palatable diet.  
Abundant evidence implicates the brain opioid systems in the regulation of food intake 
and the rewarding impact of palatable food intake
24
. Hedonic pleasure reactions have been 
operationalized in animals through ‘liking’ reactions to sweetness, which are affective 
orofacial expressions (tongue and lateral tongue protrusions) that are homologous in human 
infants, monkeys, horses and rats
32
. The neural mechanisms associated with hedonic 
responses to palatable foods have been investigated by using selective µ-opioid receptor 
ligands to identify ‘hotspots’ in the basal ganglia, especially in the ventral pallidum (VP) and 
the nucleus accumbens (NAc)
33,34
. It has been shown that the ability of μ-opioid receptor 
agonists to increase food intake is restricted to a specific portion of the NAc shell (the 
rostrodorsal quadrant of NAc medial shell), which shows high μ-opioid receptor density33. 
Recently, it has been shown that within the same μ-opioid receptor hotspot  stimulation of δ-
opioid receptor a a subtype of opioid receptor having a prominent role in emotional 
processing, can also amplify  hedonic reactions to sweetness
35
.  
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The NAc sends projections to the VP, which also projects back to the NAc, and each 
structure is embedded in complex mesocortico-limbic circuits involving the lateral 
hypothalamus, the ventral tegmental area, the prefrontal cortex and the amygdala. Each of 
these areas is fundamental in reward and motivational processes. Similar to the NAc, the VP 
has been shown to contain a hedonic hotspot, specifically in the posterior portion
34
.  
Based on these mechanisms, μ-opioid receptor agonists have been demonstrated to 
increase the intake of palatable food with a high sugar or fat content and to increase the 
consumption of more preferred food when presented at the same time with less preferred 
food
36
. μ-opioid receptor antagonists, on the other hand, reduce binge episodes for highly 
palatable food
17,19,37–39
, confirming the critical involvement of this system in the hedonic and 
consummatory aspects of ingestive behaviour. For example, the preferential µ/k opioid-
receptor antagonist nalmefene, an effective and approved treatment for heavy alcohol 
drinking
40
, has been successfully tested in a binge-eating paradigm
17
. In this study, adolescent 
female Wistar rats were food deprived for 2 h a day and then offered 10-min access to a 
feeder containing chow followed sequentially by 10-min access to a highly preferred, but 
macronutrient-comparable, sucrose-rich diet. Those exposed to chow and high sucrose diet 
developed experience-dependent binge-like hyperphagia of the diet as well as anticipatory 
hypophagia of the less preferred alternative. ‘Binges’ were reduced dose-dependently by 
systemically injected nalmefene
17
, supporting the hypothesis that the endogenous opioid 
system promotes hedonic intake. Using the binge-eating procedure described above, the 
behavioural effects of a novel, selective µ-opioid receptor antagonist GSK1521498, currently 
in clinical development for the treatment of compulsive eating disorders and obesity, was 
tested in comparison with naltrexone (NTX), a preferential µ-opioid receptor antagonist 
clinically approved for alcoholism
37
. Both GSK1521498 and NTX reduced binge-like 
palatable food hyperphagia and food intake after instrumentally working to obtain it, 
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confirming the key role that the opioid system plays in hedonic eating behaviour. The same 
compound, GSK1521498, was tested for 4 weeks in binge-eating obese subjects and resulted 
in reduced hedonic preference, specifically for higher concentrations of sugar and fat, and 
markedly reduced calorie intake in an ad libitum buffet, particularly for more palatable 
foods
39
.  
Incentive salience in eating behaviour 
Reward processing comprises two dissociable components: an anticipatory (or appetitive) 
phase, which is directed at procuring the reward, and a consummatory phase. The 
anticipatory phase can be associated with stimuli (contextual, visual, auditory or food-
associated) or the food per se. These stimuli can have a great impact on the eating behaviour, 
as they can increase it. It has been shown, for example, that learned contextual cues potentiate 
eating in rats
41
. Berridge’s group has also demonstrated that hedonic reactions to palatable 
food can be dissociated from the motivation process regulating its intake (‘wanting’), 
showing that food intake can be stimulated without enhancing ‘liking’ reactions42.  
In animal studies, food-associated cues have been operationalized and thoroughly studied 
in the context of both Pavlovian and instrumental conditioning
43
. After repeated pairings of a 
cue, such as the presentation of a stimulus light (conditioned stimulus, CS) with the delivery 
of palatable food (unconditioned stimulus, US), the learned cue itself becomes salient, 
triggers intense urges to obtain the associated reward, and also acts as a conditioned 
reinforcer able to maintain instrumental seeking even in absence of food presentation. 
Importantly, cues paired with the delivery of palatable food become capable of promoting 
consumption even when the animals are not deprived (CS-potentiated feeding)
44
. Even in 
fully sated rats, CSs strongly promote feeding compared to neutral stimuli
45,46
. Both 
associative learning and prediction contribute to motivation for rewards. The conditioned 
stimuli gain salience and elicit incentive motivation even in absence of physiological needs. 
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Evidence from the influence of Pavlovian stimuli on instrumental behaviour is provided 
by experiments based on the specific Pavlovian-instrumental transfer (PIT) effect where 
appetitive CSs (associated with positive reinforcers such as food) can greatly enhance 
instrumental responding for the same reinforcer when presented unexpectedly (independent 
of the instrumental response). Training consists of three phases: in the first, a Pavlovian 
association is acquired between a cue and a reinforcer; in the second, an instrumental 
response is trained for the same reinforcer (without any cue); in the third, the cue is presented 
during the performance of instrumental behaviour in extinction (without any reinforcer). Such 
a procedure has shown that appetitive Pavlovian stimuli can greatly enhance instrumental 
responding for the same reinforcer (specific PIT effect). PIT has been interpreted as evidence 
that CSs can exert a motivational influence over instrumental performance
47
 (Figure 1A).  
An additional useful procedure for measuring the impact a CS may have over instrumental 
performance is the second-order schedule of reinforcement, where a stimulus that acquires its 
reinforcing properties by being paired with other, generally primary, reinforcers such as food 
or drugs, can act as a conditioned reinforcer
48
 to enhance and maintain high levels of 
instrumental responses over protracted periods of time even in the absence of the primary 
reinforcer. This procedure, used previously to study the seeking of a sexual reward as well as 
cocaine, heroin, and alcohol seeking, has been adapted in order to measure, in terms of 
instrumental responses, the motivation for the opportunity to binge on a palatable food, as 
well as the impact that ingestion of that food has on subsequent food seeking
49
. The 
procedure has temporarily distinct intervals that enable the separate assessment of 
motivational influence of the food-related CS over instrumental response before and after 
food ingestion, respectively. This allows the dissociation between pharmacological effects on 
response to food cues (during the interval before food ingestion) and effects on hedonic 
impact of the food reward (during the interval(s) after food ingestion)
37,50
 (Figure 1B).   
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A different way to study anticipatory incentive processes preceding consummatory 
behaviours mediated by hedonic mechanisms consists of analysing the phenomenon known 
as ‘anticipatory negative contrast’51. Evidence suggests that binge hyperphagia of ‘forbidden’ 
foods is linked with the refusal of otherwise acceptable alternatives in humans
52
. The 
phenomenon has been operationalized in preclinical models by exposing the animals to less 
preferred, but perhaps healthier, foods followed by highly palatable foods for restricted 
periods of time
17,37,53
: as described above, 10-min brief access to a standard chow diet, 
followed by a 10-min access to a highly palatable food
17,37
, promotes binge eating of the 
highly palatable food, and self-restriction of the otherwise acceptable chow diet (Figure 1C).    
The role of the opioid system in incentive motivation for palatable 
food 
The mesolimbic dopamine system has long been implicated in the motivational aspects of 
feeding behaviour. Exposure to either drugs or palatable food as well as to food-associated 
stimuli promotes dopamine release in the striatum. Dopamine has been demonstrated to be 
fundamental in the stimulus–reward learning that is specifically associated with the 
attribution of incentive salience to reward cues
54
. It is widely accepted, although quite 
simplistic, that motivated behaviours for food are dopamine-mediated and that hedonic 
reactions to food are opioid-mediated. Indeed, dopaminergic manipulations within or outside 
the NAc shell hotspot consistently fail to enhance positive hedonic reactions to sweet 
tastes
55,56
 but potently alter motivated ‘wanting’ for the food rewards42.  
Although there is much less consensus, it has been proposed that opioid mechanisms can 
also regulate incentive motivational processes that underlie the propensity to seek palatable 
foods. 
Striatum 
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It has been shown that opioid receptor agonists in the NAc increase motivation for food
57
. 
Recently, selective stimulation of the three major subtypes of opioid receptors via agonist 
microinjections [µ (DAMGO), δ (DPDPE), or κ (U50488H)] in the NAc shell hotspot has 
been employed, to construct anatomical maps for functional localization of consequent 
changes in hedonic ‘liking’ (assessed by affective orofacial reactions to sucrose taste) versus 
‘wanting’ (assessed by changes in food intake). In line with results from other groups that 
demonstrated that the NAc shell contributes not only to the hedonic impact of sensory 
pleasure, but also to the incentive motivation to consume foods
57, δ- and µ-opioid receptor 
stimulation enhanced the ‘wanting’ to eat more food. The real distinction between ‘wanting’ 
and ‘liking’ emerged from the effects of µ- and κ-opioid receptor stimulation: although they 
both increased the ‘liking’, only the µ-opioid receptor stimulation increased the incentive 
motivation for food.  
In contrast, opioid receptor antagonists have been shown to reduce the anticipatory 
incentive processes preceding the consummatory episodes of highly palatable food. The non-
selective opioid receptor antagonist, nalmefene, for example, blocked the anticipatory 
negative contrast in the binge-eating procedure as well as highly palatable food binge 
eating
17
. Additionally, the µ-opioid receptor antagonist GSK1521498 exerted a more specific 
effect on the impact of the hedonic value of the food and intake than did NTX, reducing the 
anticipatory chow hypophagia, before the highly palatable food was available for ingestion. 
Although the paradigm used did not include any discrete stimulus (i.e. a light), several cues 
might have served as conditioned stimuli predictive of imminent preferred food availability, 
including the test environment, the deprivation period, or even the preceding first feeder 
(chow) presentation.  
A different anticipatory contrast paradigm has been developed by Katsuura and Taha
53
, in 
which separate groups of rats were presented sequentially with 4% sucrose and then either 
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20% or 0% sucrose (Group 1: 4-20%, Group 2: 4-0%). Similar to the paradigm described 
above
17,37
, daily training in this paradigm produced robust intake of 20% sucrose (binge) 
preceded by learned hypophagia during access to 4% sucrose (anticipatory negative contrast). 
The authors then tested the effects of NTX, naltrindole (a δ-opioid receptor antagonist) and β-
funaltrexamine (a µ-opioid receptor antagonist) in the NAc shell on sucrose consumption. 
NTX and β-funaltrexamine infused into the NAc shell significantly reduced sucrose intake in 
both groups, but the suppressive effects were strongly selective and dependent upon the 
relative value of sucrose solutions within each group. Thus, they reduced sucrose 
consumption in the 4-0% group, but they decreased the 20%, and not the 4%, sucrose 
solution consumption in the 4-20% group. Although the authors interpreted the results as a 
demonstration that endogenous opioid signaling promoted consumption of the preferred food, 
since the µ-opioid receptor antagonists tested blocked the learned hypophagia (anticipatory 
negative contrast) and reduced the sucrose hyperphagia (binge); therefore, it would have been 
interesting to test the compounds on a group of animals exposed to 4% sucrose during both 
phases of the session, rather than 4-20%. In that case, a specific effect of the µ-opioid 
receptor antagonists on the anticipatory negative contrast could have resulted in an increase 
of 4% sucrose solution intake in the first phase associated with a decrease of the 20% sucrose 
solution intake in the second phase.  
External food-related cues precipitate a desire for food items, resulting in food craving 
independently of energy-homeostatic needs. In this context, opioid receptor antagonists have 
been tested in animal models aiming at investigating the role of a conditioned stimulus on 
instrumental response. In a study comparing dopamine and µ-opioid receptor stimulation in 
enhancing cue-triggered motivation for reward in PIT
26
, it was shown that opioid stimulation 
caused increased cue-triggered ‘wanting’ as well as ‘linking’ at nearly all NAc sites. Thus, µ-
opioid receptor stimulation has been shown possibly to have effects functionally identical to 
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dopamine stimulation: they both elevated ‘wanting’. Additionally, the µ-opioid receptor 
antagonist GSK1521498 has been tested in comparison with NTX on food seeking under 
second-order schedule of chocolate-flavoured pellet reinforcement, in which a CS associated 
with chocolate ingestion supports high levels of instrumental-seeking behaviour over delays 
to the delivery of a large chocolate reward
37
. Although both compounds reduced food intake, 
only GSK1521498 reduced the seeking responses for chocolate before its delivery for 
ingestion, suggesting the additional effect the opioid system has on incentive motivational 
mechanisms controlling food seeking. The higher potency of GSK1521498 compared with 
NTX has been hypothesized to be due to its increased selectivity at µ-opioid receptors and/or 
its specific action on appetitive processes underlying food selection. Several putative neural 
sites at which µ-opioid receptor antagonism may cause decreases in the propensity to seek 
food have been hypothesized. It has been shown that the dopaminergic transmission in the 
NAc has a major role in incentive motivational processing for food
34
. Therefore, µ-opioid 
receptors localized on the GABAergic interneurons in the VTA may provide one site at 
which GSK1521498 might act to decrease dopamine release in the NAc to reduce food 
seeking and incentive motivation for food.  
Additional studies confirmed the role of the striatum and the basal ganglia, specifically 
putamen and pallidum which are brain regions involved in the motivational mechanisms 
underlying eating behaviour, in cue-induced responses for highly palatable food
38
. For 
example, a 28 day treatment with GSK1521498 in obese individuals with moderate binge 
eating and was associated with reduction in pallidum/putamen responses to pictures of high-
calorie food and a reduction in motivation (measured as grip force) to view images of high-
calorie food, confirming its potential as a treatment aiming at reducing compulsive food 
seeking behaviour. 
Amygdala 
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The amygdala is the brain area hypothesised to encode the association of initially 
motivationally neutral environmental stimuli with motivationally relevant outcomes in a 
Pavlovian manner
58
. This structure is divided into several subnuclei, including the central 
(CeA) and the basal and the lateral nuclei often group as the basolateral amygdala (BLA), and 
it has connections with both the hypothalamus, striatum andmedial and orbital prefrontal 
cortical areas
58
. The CeA has been hypothesized to mediate more generalized associations 
based upon the motivational valence of the reinforcer 
59,60
, whereas the BLA has been shown 
to be required for selective cuing effects related to the identity of a particular outcome
61
. 
Incentive  specific rewards has been shown to increase when the mesocortico-limbic brain 
systems are activated
62
. Although Petrovich and colleagues reported that enhancement of 
eating by an appetitive CS is dependent on the integrity of the BLA, but not CeA
63,64
, specific 
stimulation of the µ-opioid receptor circuit in the CeA has been shown to produce elevation 
of incentive salience in rats. Specifically, µ-opioid receptor stimulation (using DAMGO 
infusions) in the CeA caused elevated incentive motivation in subjects naturally attracted by a 
predictive cue (sign-trackers) and in those naturally attracted by a reward contiguous goal cue 
(goal-trackers)
65,66
 but also elevation in ‘wanting’ under PIT67. These findings may have 
strong clinical implications in compulsive pursuit disorders involving intense motivations for 
a specific target, which is the case in binge eaters that want food and perhaps a particular 
food.  
Cortex 
It has been shown that the medial prefrontal cortex (mPFC), projecting to the amygdala 
and the lateral hypothalamus, is activated selectively by a cue that stimulates eating 
behaviour in sated rats
68
. Moreover, it has been shown that the mPFC mediates enhanced 
food consumption driven by contextual conditioned cues
69
.  
14 
 
µ-Opioid receptors within the mPFC have been shown to mediate an important function in 
overeating
70
. Naltrexone microinfused into the mPFC selectively reduced the consumption 
and the motivation to obtain highly palatable food, but not standard chow
19
.  
In humans, the µ-opioid receptor antagonist GSK1521498 was tested for 4 weeks in obese 
adults with moderate to severe binge eating and resulted in a significant reduction in 
attentional bias for food-related stimuli, quantified using objective indices of cognitive 
prioritisation of food (e.g. the visual dot probe task) and shown to be associated with the 
activation of the lateral PFC
71
, supporting the central role of µ-opioid receptors in reward-
related cognitive functions
72
. Additionally, a functional magnetic resonance imaging study 
showed that naltrexone decreased the response in the anterior and dorsal anterior cingulate 
cortex, an area involved in the processing of rewarding stimuli including food, to the 
rewarding sight and taste of chocolate
73
. 
Conclusions 
Recent evidence suggests that loss of control over food intake is the primary indicator of 
BED severity. Deficits in cognitive
74
 function and inhibitory control
75
 are considered a 
possible risk and maintenance factor for binge eating, and so are the hypersensitivity to 
motivational stimuli with high incentive salience producing a bias in attentional processing 
toward drug-related cues
76
. Obese versus lean individuals report greater sensitivity to 
reward
77
 and elevated responses to food cues in regions of the brain that encode the sensory 
properties of food. The opioid system has been extensively demonstrated to be involved in 
the hedonic and consummatory aspects of ingestive behaviour. Here in reviewing the existing 
literature we discuss the importance of the opioid system in mediating the impact of palatable 
food-conditioned stimuli on the incentive motivation for food. Drugs inhibiting opioid system 
activity may have utility in treatments intended to reduce maladaptive, palatability-driven 
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eating behaviour by reducing the motivational properties of stimuli that elicit the binge eating 
strongly associated with obesity
20,78
. 
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Tables 
 
 Features Binge-eating episodes 
History of dieting 
and sucrose 
exposure model 
12-h food deprivation is followed by 12-h 
access to sucrose solution
79,80
. 
After few days, subjects escalate sucrose 
intake during the first hour of access. 
History of dieting 
and stress model 
Repetition of cycles of food-restriction and 
refeeding. At the end of each cycle, subjects 
are exposed to a stressor
81–86
. 
After three restriction/refeeding stress 
cycles, stressed subjects escalate their 
palatable food intake. 
The limited 
access model 
Subjects are never food deprived. They are 
given sporadic, time limited access to either 
vegetable fat
87,88
 or sucrose diet
17,19,37,89–91
. 
Subjects with sporadic access to palatable 
food escalate their intake. 
 
Table 1: Summary of the most predictive binge eating preclinical models, divided into three 
major classes, as a function of the procedures used to induce binge eating in the animal. 
 
 
Drugs Effects Reference 
Nalmefene 
↓binge-like eating; ↑negative contrast    Cottone et al.
17
 
GSK1521498 
↓binge-like eating; ↑negative contrast; 
↓CS-controlled food seeking; 
↓attentional bias for food-related stimuli                                                      
Giuliano et al.
37
; Ziauddeen et al.
39
 
 
Naltrexone 
↓binge-like eating; ↑negative contrast Giuliano et al.
37
; Ziauddeen et al.
39
; 
Katsuura et al.
53
 
DAMGO 
↑liking; ↑wanting Peciña et al.
26
 ; Zhang at al.
57
; Mahler et 
al.
65,67
; DiFeliceantonio et al.
66
 
DPDPE 
↑liking; ↑wanting Zhang at al.
57
 
U50488H 
↑liking Zhang at al.
57
 
Naltrindole 
↑liking Katsuura et al.
53
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β- Funaltrexamine 
↓binge-like eating; ↑negative contrast Katsuura et al.
53
 
 
Table 2: Summary of the drugs targeting the opioid system tested on binge-eating paradigms, 
their effects, and the relative references. 
 
Legends 
 
Figure 1: Incentive salience in eating behaviour has been operationalized in the context of 
both Pavlovian and instrumental conditioning through the use of:  
A) Specific Pavlovian-Instrumental Transfer, which consists of three phases: 1, a Pavlovian 
association between cue-food; 2, an association between instrumental response-food; 3, the 
instrumental response in the presence of the cue. 
B) Second-Order Schedule of Reinforcement, which consists of two temporarily distinct 
phases: 1, during the first interval, each 10
th
 active lever press (ALP) is associated with a 
brief 1-sec CS presentation; 2, during the interval(s) following the first one, the 10
th
 active 
lever press is associated with a 20-sec CS and food delivery. 
C) Anticipatory Negative Contrast, which develops in a procedure consisting of: 1, two-hour 
food deprivation; 2, 10-min brief access to a standard chow diet; 3, 10-min brief access to a 
highly palatable food.  
